Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Neuromolecular Med. 2021 Feb 15;23(4):471–484. doi: 10.1007/s12017-021-08647-1

Fig. 2.

Fig. 2

Voluntary running distance and speed. Daily running distance (panel a) and total average running (panel b) of mice in experimental groups. Mice treated with panobinostat and entinostat covered similar distance of running compared to vehicle-treated animals. Panel c, speed of running in experimental groups did not differ significantly during the last three weeks of the study. Panel d, compared to their baseline body weight values, sham and stroke (sp = 0.032 and 0.0016, respectively) and 5 mg/kg entinostat-treated animals (ep = 0.025) gained 2–2.5 g weight by completion of the study. Vehicle and 1.7 mg/kg entinostat-treated animals (vp = 0.014 and ep < 0.001, respectively) lost ~ 2 g during the same period. N = 12/group in all panels; Pano 3.0 3 mg/kg panobinostat; Pano 10.0 10 mg/kg panobinostat; Entino 1.7 1.7 mg/kg entinostat; Entino 5.0 5.0 mg/kg entinostat